US Patent No: 7,875,677

Number of patents in Portfolio can not be more than 2000

Micellar drug delivery systems for hydrophobic drugs

ALSO PUBLISHED AS: 20090105351

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

This invention provides compositions comprising a hydrophobic drug, a biocompatible micelle forming polymer, and a biocompatible low molecular weight, water-soluble polymer. Also provided are devices for injection of such compositions and for the use of such compositions to form hydrophobic drug containing micelles within the body of a patient.

Loading the Abstract Image... loading....

First Claim

See full text

all claims..

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
THE UNIVERSITY OF BRITISH COLUMBIAVANCOUVER549

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Burt, Helen M Vancouver, CA 30 215
Jackson, John K Vancouver, CA 37 312
Zastre, Jason Vancouver, CA 4 5

Cited Art Landscape

Patent Info (Count) # Cites Year
 
BRISTOL-MYERS SQUIBB COMPANY (8)
5,248,796 Taxol derivatives 76 1992
5,300,638 Asymmetric synthesis of taxol side chain 30 1992
5,272,171 Phosphonooxy and carbonate derivatives of taxol 93 1992
5,254,580 7,8-cyclopropataxanes 118 1993
5,294,637 Fluoro taxols 67 1993
5,380,751 6,7-modified paclitaxels 36 1993
5,412,092 N-substituted 2-azetidinones 43 1993
5,395,850 6,7-epoxy paclitaxels 21 1994
 
AVENTIS PHARMA S.A. (6)
4,814,470 Taxol derivatives, their preparation and pharmaceutical compositions containing them 242 1987
5,393,895 Process for obtaining 10-deacetylbaccatin III 8 1993
5,393,896 Process for obtaining 10-deacetylbaccatin III 7 1993
5,717,103 Process for the esterification of baccatin III and of 10-deacetylbaccatin III 3 1995
5,736,366 Process for obtaining 10-deacetylbaccatin III 6 1995
5,977,375 Esters of baccatin III and 10-deacetylbaccatin III 1 1997
 
ANGIOTECH PHARMACEUTICALS, INC. (5)
5,716,981 Anti-angiogenic compositions and methods of use 682 1995
5,886,026 Anti-angiogenic compositions and methods of use 216 1995
5,994,341 Anti-angiogenic Compositions and methods for the treatment of arthritis 65 1995
6,506,411 Anti-angiogenic compositions and methods of use 75 1999
6,544,544 Anti-angiogenic compositions and methods of use 133 2001
 
BOSTON SCIENTIFIC SCIMED, INC. (5)
5,811,447 Therapeutic inhibitor of vascular smooth muscle cells 195 1995
5,981,568 Therapeutic inhibitor of vascular smooth muscle cells 275 1997
6,306,421 Therapeutic inhibitor of vascular smooth muscle cells 84 1997
6,231,600 Stents with hybrid coating for medical devices 365 1999
6,358,989 Therapeutic inhibitor of vascular smooth muscle cells 48 1999
 
VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY (4)
5,059,699 Water soluble derivatives of taxol 115 1990
5,352,805 Water soluble derivatives of taxol 16 1991
5,278,324 Water soluble derivatives of taxol 55 1991
5,411,984 Water soluble analogs and prodrugs of taxol 16 1992
 
IPXMEDICAL, LLC (3)
6,515,016 Composition and methods of paclitaxel for treating psoriasis 28 1997
6,495,579 Method for treating multiple sclerosis 15 1998
6,689,803 Compositions and methods for treating surgical adhesions 69 2002
 
SAMYANG BIOPHARMACEUTICALS CORPORATION (3)
6,210,717 Biodegradable mixed polymeric micelles for gene delivery 25 1998
6,322,805 Biodegradable polymeric micelle-type drug composition and method for the preparation thereof 35 2000
6,616,941 Polymeric composition for solubilizing poorly water soluble drugs and process for the preparation thereof 14 2001
 
FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION (2)
5,350,866 10-desacetoxytaxol derivatives 71 1992
5,283,253 Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them 93 1992
 
KIM PH.D., SUNG WAN (2)
6,004,573 Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties 138 1997
6,117,949 Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties 57 1998
 
R.P. SCHERER CORPORATION (2)
5,645,856 Delivery systems for hydrophobic drugs 98 1995
5,827,541 Process for preparing solid pharmaceutical dosage forms of hydrophobic substances 26 1996
 
SUPERGEN, INC. (2)
6,017,948 Water-miscible pharmaceutical compositions 17 1998
6,136,846 Formulation for paclitaxel 35 1999
 
The Scripps Research Institute (2)
5,274,137 Intermediates for preparation of taxols 32 1992
5,422,364 Water soluble taxol derivatives 48 1993
 
ABBOTT LABORATORIES (1)
5,440,056 9-deoxotaxane compounds 46 1994
 
ABRAXIS BIOSCIENCE, LLC (1)
5,916,596 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof 127 1996
 
APHIOS CORPORATION (1)
5,776,486 Methods and apparatus for making liposomes containing hydrophobic drugs 37 1996
 
BAKER NORTON PHARMACEUTICALS, INC. (1)
5,968,972 Method for increasing the oral bioactivity of pharmaceutical agents 24 1996
 
BASF AKTIENGESELLSCHAFT (1)
5,939,454 Fungicidal mixtures of an oxime ether carboxylic acit amide with a dithiocarbamate 1 1998
 
BIONUMERIK PHARMACEUTICALS, INC. (1)
6,040,330 Pharmaceutical formulations of taxanes 14 1999
 
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (1)
5,955,509 pH dependent polymer micelles 194 1997
 
BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (1)
5,279,949 Process for the isolation and purification of taxol and taxanes from Taxus spp 39 1992
 
CEPHALON LIMITED (1)
6,107,332 Hydrolysis-promoting hydrophobic taxane derivatives 1 1999
 
CORNELL UNIVERSITY (1)
6,369,037 Controlled release of doxorubicin 1 2000
 
DUKE UNIVERSITY (1)
5,827,533 Liposomes containing active agents aggregated with lipid surfactants 32 1997
 
E. I. DU PONT DE NEMOURS AND COMPANY (1)
4,650,913 Sulfinate-initiated addition of perfluorinated iodides to olefins 12 1984
 
EFRAT BIOPOLYMERS LTD. (1)
6,365,173 Stereocomplex polymeric carriers for drug delivery 40 1999
 
Gerhard Gergely (1)
5,834,019 Pharmaceutical formulation containing a hydrophobic active substance and an effervescent system 7 1996
 
IMPERIAL CHEMICAL INDUSTRIES PLC (1)
4,526,938 Continuous release formulations 248 1983
 
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (1)
5,543,158 Biodegradable injectable nanoparticles 272 1993
 
MAYNE PHARMA (USA), INC. (1)
5,202,448 Processes of converting taxanes into baccatin III 32 1992
 
NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT (1)
4,942,184 Water soluble, antineoplastic derivatives of taxol 153 1988
 
PHARMACIA & UPJOHN S.P.A. (1)
5,362,831 Polymer-bound paclitaxel derivatives 97 1993
 
PROTHERICS SALT LAKE CITY, INC. (1)
6,592,899 PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water 15 2001
 
RESEARCH DEVELOPMENT CORPORATION OF JAPAN (1)
5,510,103 Physical trapping type polymeric micelle drug preparation 44 1995
 
Rhone-Poulenc S.A. (1)
5,453,521 Process for obtaining 10-deacetylbaccatin III 13 1993
 
Rhone-Poulenc Sante (1)
4,857,653 Process for the preparation of taxol and 10-deacetyltaxol 177 1987
 
SUCAMPO AG (1)
5,229,529 Method of producing .alpha.,.beta.-unsaturated ketolactones 21 1992
 
Supernus Pharmaceuticals, Inc. (1)
5,430,021 Hydrophobic drug delivery systems 49 1994
 
SUPRATEK PHARMA INC. (1)
6,153,193 Compositions for targeting biological agents 12 1995
 
SYNGENTA LIMITED (1)
4,745,160 Biodegradable amphipathic copolymers 139 1985
 
TEKMIRA PHARMACEUTICALS CORPORATION (1)
5,478,860 Stable microemulsions for hydrophobic compound delivery 54 1993
 
UNIVERSITY OF DELAWARE (1)
4,419,340 Controlled release of anticancer agents from biodegradable polymers 50 1980
 
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (1)
5,200,534 Process for the preparation of taxol and 10-deacetyltaxol 62 1992
 
VESTAR, INC. (1)
5,484,809 Prodrugs for oral administration containing taxol or substituted taxol covalently bound to a phospholipid 45 1994
 
Other [Check patent profile for assignment information] (1)
5,843,891 Pharmaceutical acceptable compositions containing an alcohol and a hydrophobic drug 30 1995

Patent Citation Ranking

Forward Cite Landscape

  • No Forward Cites to Display

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Jul 25, 2014
7.5 Year Payment $3600.00 $1800.00 $900.00 Jul 25, 2018
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jul 25, 2022
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00